Respiratory Research
Respiratory Research is a peer-reviewed respiratory medicine journal published by BioMed Central, part of the Springer Nature group. Founded in 2000 and fully open access, it publishes high-quality translational laboratory and clinical research on all aspects of respiratory medicine and related diseases.《呼吸研究》（Respiratory Research）是一份由 BioMed Central（施普林格自然集团旗下）出版的呼吸医学同行评审学术期刊。该刊创刊于 2000 年，是完全开放获取刊物，刊载呼吸医学及相关疾病各方面的高质量转化实验室与临床研究。
Scope
The journal's editorial stance takes translation and clinical work as equally weighted, accepting both laboratory translational and clinical research and requiring that one or the other bear directly on the mechanism, diagnosis or treatment of respiratory disease. It describes its readership as pulmonologists, allergists, immunologists, researchers, healthcare workers and medical students, a composition that obliges its content to serve both basic and clinical sides. Its principal subject areas include:本刊的取稿立场是「以转化与临床并重为取向」，即同时接受实验室转化研究与临床研究，并要求两者之一与呼吸疾病的机制或诊疗直接相关。刊物自述面向肺科医师、过敏症医师、免疫学家以及研究者、医务工作者与医学生，这一读者构成决定了其内容须兼顾基础与临床两侧。收文覆盖的主要方向包括：
- Asthma and allergy: mechanisms of airway inflammation, phenotypic classification and targeted therapy in asthma.哮喘与过敏： 哮喘的气道炎症机制、表型分型与靶向治疗。
- Chronic obstructive pulmonary disease: pathogenesis, phenotypes and real-world evidence of drug efficacy in chronic obstructive pulmonary disease.慢性阻塞性肺疾病： 慢阻肺的发病机制、表型与药物疗效的真实世界证据。
- Pulmonary fibrosis and interstitial lung disease: mechanisms of epithelial remodelling in pulmonary fibrosis, imaging and the appraisal of progression.肺纤维化与间质性肺病： 肺纤维化的上皮重塑机制、影像与进展评价。
- Acute respiratory distress and infection: immune mechanisms and treatment in acute respiratory distress syndrome and pulmonary infection.急性呼吸窘迫与感染： 急性呼吸窘迫综合征、肺部感染的免疫机制与救治。
- Lung cancer and respiratory physiology: molecular mechanisms in lung cancer, cell death pathways such as ferroptosis, and methods of respiratory physiological and imaging assessment.肺癌与呼吸生理： 肺癌分子机制、铁死亡等细胞死亡途径，以及呼吸生理与影像评估方法。
The journal is fully open access, listed in the directory of open access journals, with article processing charges set by the publisher according to article type. The publisher states an official median of 4 days from submission to first decision, a figure that includes editorial screening. The journal is indexed in the Science Citation Index Expanded and carries a 2025 impact factor of 5.7 and a five-year figure of 5.9.该刊为完全开放获取刊物，文章处理费由出版方按期刊类型设定，被开放获取期刊目录收录。出版方官方公布投稿至首次决定中位数为 4 天，该口径包含编辑部初筛。该刊被科学引文索引扩展版收录，2025 年影响因子 5.7、五年影响因子 5.9。
History
- Founding (2000): the journal was founded in 2000 and published by BioMed Central. The founding title is the current one, with no predecessor, and the library's record of the founding year agrees with the publisher.创刊（2000年）： 本刊创刊于 2000 年，由 BioMed Central 出版；创刊刊名即为现名，无前身刊。库内所记创刊年与出版方一致。[1]
- Publisher history: the journal was published by BioMed Central at founding, and that imprint was later folded into the Springer Nature group, within which it now sits. The library's publisher record of BioMed Central agrees with the current arrangement.出版方沿革： 创刊后由 BioMed Central 出版，该社后并入施普林格自然集团，现属集团旗下；库内所记出版方 BioMed Central 与现行安排一致。[2]
- Current editor: Dale Tang serves as editor-in-chief, holding MD and PhD degrees, his editorship recorded in the editors' block of the publisher's official journal page. The library's previous record of two editors has been corrected to a single editor in line with the official page.现任主编： 戴尔·唐（Dale Tang）任主编，医学博士、哲学博士；其主编身份在出版方官方期刊页的编者栏中载明。库内原记两位主编，已按官方页更正为单主编。[2]
- Open access arrangements: the journal has been fully open access since launch and is listed in the directory of open access journals. Article processing charges are set by the publisher according to article type, with waivers available to corresponding authors in low-income countries.开放获取安排： 该刊自创刊起即为完全开放获取，被开放获取期刊目录收录；文章处理费由出版方按期刊类型设定，低收入国家通讯作者可申请减免。[3]
- Official review timing: the publisher states an official median of 4 days from submission to first decision, a figure that includes editorial screening. The library's previous note of a relatively slow four to eight weeks had no official basis and has been deleted.官方审稿口径： 出版方官方公布投稿至首次决定中位数为 4 天，该口径包含编辑部初筛；库内原记审稿「相对较慢，4 至 8 周」无官方依据，已删除。[1]
- Metric trend: the 2025 impact factor of 5.7, together with a five-year figure of 5.9, places the journal in the medical class 2 zone of the Chinese Academy of Sciences ranking, with the respiratory system sub-category at zone 2.指标走势： 影响因子自 2025 年的 5.7 与五年影响因子 5.9 共同刻画该刊位置；中科院分区中列于医学大类二区、呼吸系统小类二区。[2]
Editors
The journal operates under a single editor-in-chief appointed by the publisher, with an editorial board in support, and manuscripts submitted through the publisher's own submission system. The publisher states a time to first decision, and the composition of the editorial office is taken from the masthead.本刊实行主编负责制，主编由出版方任命并主持编辑部，另设编委会；稿件经出版方自有的投稿系统投递。官方公布首次决定时长，编辑部构成以刊头署名为准。
- Dale Tang (current editor-in-chief): holding MD and PhD degrees and long active in respiratory disease research, his editorship recorded in the editors' block of the publisher's official journal page.戴尔·唐（现任主编）： 医学博士、哲学博士，长期从事呼吸疾病研究；其主编身份在出版方官方期刊页的编者栏中载明。[2]
- Board composition: the journal describes itself as boasting a renowned editorial board whose members come from around the world, forming its international review capacity, a composition consistent with its fully open access and international positioning.编委会构成： 该刊自述拥有一支知名编委会，成员来自世界各地，构成其国际化的评审力量；这一构成与该刊完全开放获取的国际定位相符。[2]
- Editorial stance: the journal describes itself as publishing high-quality translational laboratory and clinical research on all aspects of respiratory medicine and related diseases, together with review and commentary, a stance that covers both basic and clinical sides.取稿立场： 刊物自述刊载呼吸医学及相关疾病各方面的高质量转化实验室与临床研究，以及综述与评论文章；这一立场使其同时覆盖基础与临床两侧。[2]
- Acceptance and speed: the publisher publishes only the median of 4 days from submission to first decision, a figure that includes editorial screening. The library's previous note of a relatively slow four to eight weeks had no official basis and has been deleted.录用与时效： 出版方仅公布投稿至首次决定中位 4 天，该口径含编辑部初筛；库内原记审稿「相对较慢，4 至 8 周」无官方依据，已删除。[2]
- Standing in the field: the journal is regarded as one of the leading fully open access titles in respiratory medicine, its translational and clinical research cited directly in respiratory guidelines, and its papers were downloaded more than 4.8 million times in 2025.学科地位： 该刊被视为呼吸医学领域领先的完全开放获取刊物之一，其转化与临床研究常被呼吸病指南直接引用，2025 年论文下载逾四百八十万次。[2]